Former Chief Scientific Officer at Dong-A ST

Ildong Pharmaceutical announced on April 1 that it has recruited Dr. Jaehong Park and appointed him as the new President and Head of Research and Development (R&D).

Jaehong Park, President and Head of R&D at Ildong Pharmaceutical. Ildong Pharmaceutical

Jaehong Park, President and Head of R&D at Ildong Pharmaceutical. Ildong Pharmaceutical

View original image

Born in 1969, President Park obtained his bachelor's and master's degrees in biotechnology from Yonsei University, and earned his Ph.D. from Boston University School of Medicine in the United States. He subsequently worked as a researcher at institutions including Harvard Medical School.


He then accumulated diverse experience in new drug clinical development and commercialization at global pharmaceutical companies such as Janssen, Takeda Pharmaceutical, and Boehringer Ingelheim. In 2022, he joined Dong-A ST as Chief Scientific Officer (CSO), leading the company's R&D operations.



Going forward, President Park will oversee all R&D activities at Ildong Pharmaceutical, including new drug research and development.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing